Slide 1: Presentation to Investors cover letter
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 6 October 2017 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (15 pages by email) Dear Madam PRESENTATION TO
Slide 2: Biotron Limited Investor Update October 2017
For personal use only BIOTRON LIMITED (ASX:BIT) Investor Update October 2017
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presenta4on may contain forward-looking statements with respect to the financial condi4on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec4ves of its management. These statement
Slide 4: Biotron Limited - Investment Highlights
Biotron Limited - Investment Highlights • Spun out from John Cur4n School of For personal use only • Infec4ous disease focus Medical Research at the Australian • Phase 2 clinical program - HIV-1 Na4onal University eradica4on trial data expected 4Q17 • Listed on ASX (ASX:BIT) • Pipeline of earlier st
Slide 5: Biotron – Leader in Antiviral Drug Development
Biotron – Leader in AnEviral Drug Development For personal use only • Exper4se is the development of a new class of an4viral drugs targe4ng viral-encoded viroporin proteins • Viroporins are present in broad range of viruses: Influenza (M2), HIV-1 (Vpu), HCV (p7), Dengue and West Nile (M protein), SAR
Slide 6: Viroporins
Viroporins For personal use only • Small hydrophobic proteins with ion channel ac4vity • Form hydrophilic pores in host cell membranes • Key stages of the viral cycle such as virus uncoa4ng, transport and matura4on are ion-influenced processes in many viral species • Crucial for viral pathogenicity d
Slide 7: HIV-1 Eradication
HIV-1 EradicaEon For personal use only Current drugs do not eradicate HIV-1 virus • HIV-1 remains hidden in reservoirs, leading to chronic, life-long infec4on – Invisible to body’s immune defenses – Not sensi4ve to an4-HIV-1 drugs • New mode of ac4ons drugs are needed to eradicate or cure HIV-1 infe
Slide 8: BIT225 Targets HIV-1 in Virus Reservoirs
BIT225 Targets HIV-1 in Virus Reservoirs • BIT225 inhibits assembly and budding of new virus in macrophage reservoirs For personal use only • Phase 1b/2a trial (004) demonstrated that BIT225 can reduce HIV-1 levels in macrophage cells in vivo, paralleling in vitro studies (Wilkinson et al, J An4micr
Slide 9: Phase 2 Trial – BIT225-009 In Progress
Phase 2 Trial – BIT225-009 In Progress For personal use only BIT225 or placebo added to ART xx x x x x x • 36 HIV-1+ve, treatment-naïve subjects commencing ART • Randomised 2:1 (drug:placebo) • BIT225 or placebo added to ART for first 12 weeks of treatment • Read-out • Impact on viral load kine4cs; r
Slide 10: BIT225 – First of a New Class of HCV DAA Drugs
BIT225 – First of a New Class of HCV DAA Drugs • Targets HCV p7 protein - Inhibits viral assembly and infec4vity For personal use only • Pan-genotype ac4vity: • Ac4ve in vitro against all main genotypes • Clinical ac4vity against HCV GT 1 (1a and 1b) and GT 3 demonstrated in Phase 2a trials • Seekin
Slide 11: Core Technology Drives Rich Compound Library
Core Technology Drives Rich Compound Library For personal use only Library of compounds designed to target viroporins: Ini4ally >250 compounds designed and synthesised; library now ~350 OTHER “HITS” IN LIBRARY include: • Influenza A and B • Hepa44s B virus (HBV) • Coronaviruses (Including SARS) • Eps
Slide 12: Unlocking Value in Compound Library
Unlocking Value in Compound Library • Renewed industry interest in targe4ng viral diseases including For personal use only • Respiratory diseases e.g. Respiratory syncy4al virus (RSV) & Influenza • Hepa44s B virus • Tropical diseases including Dengue • Influenza, Ebola, Zika and MERS-CoV outbreaks hav
Slide 13: Commercialisation: Multiple Partnering Opportunities
CommercialisaEon: MulEple Partnering OpportuniEes Commercial acEviEes focused on finding partners for individual targets or enEre pla`orm For personal use only • HIV-1 Program • Significant value inflec4on expected in late 2017 on basis of Phase 2 data • Aim to partner at conclusion of current Phase 2
Slide 14: Investment Highlights
For personal use only Investment Highlights TargeEng viroporin proteins with a rapid screening proprietary primary NOVEL ANTIVIRAL bacterial cell-based pla`orm - a library of over 350 compounds with acEvity PLATFORM against a range of viruses. Clinical and Preclinical programs in indicaEons with hig
Slide 15: For personal use only
For personal use only Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au 15 20